School of Advanced Warfighting

WOLF-X Prototype Selected for the RCV Program Phase 1 Contract Award to McQ

Retrieved on: 
Thursday, September 28, 2023
McQ Inc, Next Generation Combat Vehicle, NAMC, Compact, HDT, Unitary state, Federal government of the United States, Government, United States Army, McQ, School of Advanced Warfighting, United States Department of the Army, RCV, BAE Systems, Growth

SOLON, Ohio, Sept. 28, 2023 /PRNewswire/ -- Team HDT, primed by McQ, announced today the selection of the WOLF-X by the U.S. Army for the Remote Combat Vehicle (RCV) program Phase I contract award.

Key Points: 
  • SOLON, Ohio, Sept. 28, 2023 /PRNewswire/ -- Team HDT, primed by McQ, announced today the selection of the WOLF-X by the U.S. Army for the Remote Combat Vehicle (RCV) program Phase I contract award.
  • "We're delighted our WOLF-X RCV system was selected for the RCV Program's Phase I test and evaluation," said Kevin McSweeney, HDT Global President and CEO.
  • Purpose-built for the US Army RCV program, the WOLF-X exceeds all requirements and is engineered to accommodate future growth requirements.
  • With superior performance characteristics optimized for the RCV performance specifications, the WOLF-X is a force-multiplying capability for our nation's Warfighters.

SPEE3D CHOSEN TO BRING COLD SPRAY ADDITIVE MANUFACTURING TECHNOLOGY TO THE US NAVAL POSTGRADUATE SCHOOL (NPS)

Retrieved on: 
Wednesday, August 23, 2023
Cold spray additive manufacturing, Consortium, Defense, CAM, NAVSEA, Research, Element, CSAM, Ship, School of Advanced Warfighting, US, Laser, Naval Postgraduate School, Risk, Marines, Navy, MRO, Education, Maintenance, Coast guard, Pennsylvania State University, Aircraft, 3D printing, Operation

The XSPEE3D printer will be utilized by the US Naval Postgraduate School by military graduate students and Ph.D. candidates, as well as research and development professionals.

Key Points: 
  • The XSPEE3D printer will be utilized by the US Naval Postgraduate School by military graduate students and Ph.D. candidates, as well as research and development professionals.
  • CAMRE plans to leverage the XSPEE3D printer and its proprietary Cold Spray Additive Manufacturing (CSAM) technology to explore its Maintenance, Repair, and Operations (MRO) role for ships and vessels – both surface and undersea – and aircraft and ground equipment.
  • “Uniquely, it runs on heated compressed air and does not require inert gasses or lasers, reducing risk to the operator.
  • XSPEE3D offers a containerized, ruggedized, deployable additive manufacturing capability that can function in austere environments while exposed to the elements.

BIO 300 Featured at the 2023 Military Health System Research Symposium

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Health, General Health, Pharmaceutical, Veterans, Infectious Diseases, Military, Other Defense, Defense, COVID-19, Clinical Trials, BIO, Radiation, Acute radiation syndrome, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, Policy, Uniformed Services University of the Health Sciences, Armed Forces Radiobiology Research Institute, United States Department of the Army, Research, Government, Military personnel, DOD, Federal government of the United States, Humanetics, Patient, Data, Outline of health sciences, Privacy and the US government, FDA, Department of Defence, Vaccine, School of Advanced Warfighting

Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th.

Key Points: 
  • Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th.
  • BIO 300 is being developed for use by military personnel, first responders, and at-risk civilian populations to prevent the harmful and deadly effects of ARS.
  • There is an urgent need for drugs like BIO 300, as no FDA-approved countermeasures provide prophylactic protection against ARS.
  • Professor Singh’s presentation highlighted the research on BIO 300 that has positioned it as the most advanced prophylactic medical countermeasures currently under development for ARS.

Acumentrics, Inc. Is Awarded CHS-5 Contract on Additional Power Products

Retrieved on: 
Monday, April 17, 2023
Defense, Technology, Batteries, Military, Government Technology, Hardware, Contracts, Business development, United States Department of Defense, Marketing, App Store (iOS/iPadOS), School of Advanced Warfighting

He added that Acumentrics is dedicated to providing Warfighters with the most advanced, reliable, and configurable power solutions to support their mission-critical systems.

Key Points: 
  • He added that Acumentrics is dedicated to providing Warfighters with the most advanced, reliable, and configurable power solutions to support their mission-critical systems.
  • This will give them the necessary overmatch capabilities to increase their lethality, survivability, and efficiency while operating at the tactical edge.
  • In essence, the addition of these power solutions will greatly improve the Warfighters' operational capabilities.
  • Its expertise in Trusted Power Innovation® begins with field-proven Ruggedized Uninterrupted Power Supplies (RUPS™) that provide power conditioning, conversion, and distribution for airborne, shipboard, ground and mobile applications.

Xcelerate Solutions Wins DLA Recompete to Continue Modernization Efforts

Retrieved on: 
Friday, September 2, 2022
Xcelerator, Solution, View, United States Department of Defense, DLA, JETS, Multimedia, Defense Logistics Agency, School of Advanced Warfighting, History, Defense, Military personnel, Acquisition, Contract, Efficiency, Management, Risk management

Through this task order, Xcelerate will continue to provide critical support to DLA and the JCXS program and their mission of providing agile, responsive, and global joint expeditionary acquisition business systems.

Key Points: 
  • Through this task order, Xcelerate will continue to provide critical support to DLA and the JCXS program and their mission of providing agile, responsive, and global joint expeditionary acquisition business systems.
  • This strategic win leverages Xcelerate's more than 10-year history of outstanding performance with DLA delivering development and sustainment support services.
  • "Xcelerate is proud to continue supporting this mission critical program to provide our Warfighters a suite of tools to help with their operational and mission needs," said Xcelerate CEO, Mark Drever.
  • Xcelerate Solutions exists to create innovative solutions that deliver results, manage risk from individuals to systems, and accelerate time to value.

AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and Veterans

Retrieved on: 
Tuesday, July 12, 2022
Defense, Veteran, United States Army Futures Command, Precision medicine, Anxiety, Speech disorder, APTS, Product manager, National Defense Strategy (United States), Compliance, Course Correction, Diagnosis, Medicine, Vaccine, Artificial intelligence, Multimedia, Psychiatry, Service, Combat support agency, Comorbidity, Survival, United States Army Medical Research and Development Command, Digital, Defense Health Agency, Patient, CEO, Digital health, NEW, Program, NIH, Depression, Time, National, APT, United States Army Medical Materiel Agency, Health, AI, FDA, Quality of life, Research, Unified combatant command, Military Health System, Post-traumatic stress disorder, DHA, Biomarker, Pharmaceutical industry, Medical device, PTSD, School of Advanced Warfighting

By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.

Key Points: 
  • By optimizing personalized treatment matching, the PTSD-DT Program and AiCure aim to improve service members' quality of life and maintain troop readiness, while also informing the development of future therapies.
  • Eighty percent have at least one additional comorbidity such as depression, anxiety or substance abuse disorder, complicating diagnosis and treatment further1.
  • Despite the societal, financial, and emotional strain that PTSD exerts upon patients, treatment options remain scarce, with only two FDA approved therapies.
  • DHA supports the National Defense Strategy and Service Military Departments by leading the Military Health System as an integrated, highly-reliable system of readiness, medical training, and health.

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

Retrieved on: 
Thursday, March 17, 2022
Department, Research, Technology, Development, Absorption, School of Advanced Warfighting, United States Army Medical Research Institute of Infectious Diseases, Skin, Risk, Biosafety level, United States Army Medical Research and Development Command, Defense, Temperature, RVSV-ZEBOV vaccine, Inhalation, Veteran, Solubility, COVID-19, Government, Infection, Pandemic, Freezing, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Biosafety, Program, Health, Therapy, Nose, NASDAQ, Severe acute respiratory syndrome coronavirus 2, TFF, Biological warfare, GLOBE, Annual report, Military, Vaccine, FDA, Institute, Safety, CRADA, Company, Military medicine, Pharmaceutical industry, Virology

Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.

Key Points: 
  • Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.
  • Current medical countermeasures have become less effective in recent months as new COVID-19 variants have emerged, saidGlenn Mattes, President & Chief Executive Officer ofTFF Pharmaceuticals.
  • TFF Pharmaceuticals continues to engage with various government and defense contracting agencies to utilize its Thin Film Freezing technology platform to formulate dry powder vaccines and therapeutics for mucosal delivery.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability.